<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978208</url>
  </required_header>
  <id_info>
    <org_study_id>ATB-346-P2B-DRF</org_study_id>
    <nct_id>NCT03978208</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Phase 2B Study to Assess the Efficacy and Safety of a 14-Day Dosing Regimen of 3 Doses of ATB-346 Versus Placebo, Orally Administered Once Daily to Patients Diagnosed With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antibe Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veristat, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Antibe Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a 14-day dosing regimen of
      ATB-346 at doses of 150 mg, 200 mg and 250 mg compared to placebo in reducing osteoarthritis
      knee pain as measured by changes in the post-treatment WOMAC subscale pain score relative to
      each patient's pretreatment baseline WOMAC assessment.Safety will be assessed via
      measurements of vital signs and clinical laboratory tests at baseline and at various time
      points during the study, patient monitoring, and by the documentation of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a 14-day dosing regimen of
      once daily administration of ATB-346 at doses of 150 mg, 200 mg and 250 mg compared to
      placebo in reducing osteoarthritis knee pain as measured by changes in the post-treatment
      WOMAC subscale pain score relative to each patient's pretreatment baseline WOMAC assessment.A
      total of 360 evaluable patients are planned in this study: 250 mg (n=120); 200 mg (n=120);
      150 mg (n=60); placebo (n=60).

      Safety will be assessed via measurements of vital signs and clinical laboratory tests at
      baseline and at various time points during the study, patient monitoring, and by the
      documentation of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">December 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Overencapsulation of study drug tablets</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>5-item pain intensity measure</measure>
    <time_frame>Previous 48 hours</time_frame>
    <description>Self reported pain intensity over the past 48 hours. Each item is scored 0-10 (0 = no pain; 10 = pain as bad as can be), yielding a total between 0 and 50</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-item stiffness intensity measure</measure>
    <time_frame>Previous 48 hours</time_frame>
    <description>Self reported pain intensity over the past 48 hours. Each item is scored 0-10 (0 = no pain; 10 = pain as bad as can be), yielding a total between 0 and 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17-item difficulty performing daily activities measure</measure>
    <time_frame>Previous 48 hours</time_frame>
    <description>Self reported pain intensity over the past 48 hours. Each item is scored 0-10 (0 = no pain; 10 = pain as bad as can be), yielding a total between 0 and 170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of whole blood cyclo-oxygenase activity</measure>
    <time_frame>After 1, 4 and 14 days of treatment dosing.</time_frame>
    <description>Thromboxane B2 (TXB2) blood levels (pg/mL) will be measured after 1, 4 and 14 days of treatment. samples taken on days 1, 4 and 14. Decreases (measured in pg/mL) in the blood levels of thromboxane B2 are a direct measure of the effect of treatment on cyclo-oxygenase activity and the reduced production of this inflammatory mediator, i.e., thromboxane B2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with genetic variations in the drug modifying enzyme CYP2C9 that may alter the metabolism of ATB-346 will be investigated.</measure>
    <time_frame>Samples will be retained through study completion and analyzed within 1 year of study initiation.</time_frame>
    <description>CYP2C9 isoforms will be measured in one blood sample taken prior to study drug dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Pre-study and days 4, 14 and 24.</time_frame>
    <description>The safety of ATB-346 will be monitored via on study and two week post study physician and clinical laboratory assessments.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATB-346 mid-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATB-346 standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Overencapsulated placebo tablet taken by mouth once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATB-346 low dose</intervention_name>
    <description>Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients</description>
    <arm_group_label>Active Comparator</arm_group_label>
    <other_name>Non-active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATB-346 mid-dose</intervention_name>
    <description>Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients</description>
    <arm_group_label>ATB-346 mid-dose</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATB-346 standard dose</intervention_name>
    <description>Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients</description>
    <arm_group_label>ATB-346 standard dose</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis greater than 2 years duration requiring the use of regular therapies, e.g.
             oral or topical anti-inflammatories, acetaminophen, topical capsaicin

          -  Between the ages of 40 to 75

          -  BMI ≤40

          -  Patients must be unlikely to procreate or agree to the use of acceptable contraceptive
             regimens from first drug administration , during the study, and for at least 30 days
             after the last dose

          -  Patients must not have used aspirin or naproxen-containing medications for 7 days
             prior to study entry

          -  Patients must not have used any anti-inflammatory medications or acetaminophen for 5
             days prior to study entry

          -  Patients must show a ≥10-point increase in WOMAC Visual Analog Score between their
             screening visit and baseline study entry visit

        Exclusion Criteria:

          -  Females who are pregnant or breastfeeding

          -  Seated and resting pulse rate less than 50 beats per minute (bpm) or more than 100 bpm
             at screening

          -  Seated and resting blood pressure below 100/60 mmHg or higher than 140/90 mmHg at
             screening

          -  History of significant hypersensitivity to naproxen, other non-steroidal
             anti-inflammatory agents, or any related products (including excipients of the
             formulations) as well as severe hypersensitivity reactions (like angioedema) to any
             drugs

          -  Patients with a history of GI bleeding or ulceration

          -  Patients refractory to NSAIDs

          -  Presence of significant gastrointestinal, liver, or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or know to potentiate or predispose patients to undesired effects

          -  Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic, or dermatologic disease as determined by the
             investigator

          -  Suicidal tendency, history of/or disposition to seizures, state of confusion

          -  History of hepatic disease

          -  Maintenance therapy with any drug, including gastroprotective agents such as proton
             pump inhibitors, H2 receptor antagonists, sucralfate, etc., or significant history of
             drug dependency or alcohol abuse (&gt;3 units of alcohol per day, intake of excessive
             alcohol, acute or chronic)

          -  Any clinically significant illness in the previous 30 days before Day 1 of this study

          -  Use of any enzyme-modifying drugs, including strong inhibitors of CYP enzymes (such as
             cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole,
             ketoconazole, diltiazem, and HIV antivirals) and strong inducers of CYP enzymes (such
             as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John`s
             Wort) in the previous 30 days before Day 1 of this study

          -  Any history of tuberculosis and/or prophylaxis for tuberculosis

          -  Positive H. Pylori Urea Breathe Test

          -  Positive urine screening of alcohol and/or drugs of abuse at the screening visit

          -  Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAg) or
             anti-Hepatitis C Virus (HCV) tests

          -  Females who are pregnant according to a positive serum pregnancy test

          -  Patients who took an Investigational Product (in another clinical trial) in the
             previous 30 days before Day 1 of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Veristat</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Vaughan, PhD</last_name>
    <phone>905 831 9290</phone>
    <email>david.vaughan@antibethera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Viable Clinical Research Corp</name>
      <address>
        <city>Mission</city>
        <state>British Columbia</state>
        <zip>V2V 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Del Vicario, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocean West Research Clinic</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3Z 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Lowe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>James K. Lai MD Inc</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1K3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. MB Jones Inc</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 4A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research Inc.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney Brittain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aggarwal and Associates Limited</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naresh Aggarwal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Burlington North)</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Salter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Etobicoke Medical Centre</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8Z 5W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Weinberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dawson Clinical Research</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug Friars, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Allen Greenspoon Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Greenspoon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tytus Richard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milestone Research Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Dzongowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KGK Science Inc</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Crowley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malton Medical Clinic</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4V 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Zidel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Henein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Street Medical Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1G6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zahavi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bluewater Clinical Research Group Inc</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John O'Mahony, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viable Clinical Research Corp</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Butt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Steven V. Zizzo Medicine Professional Corporation</name>
      <address>
        <city>Stoney Creek</city>
        <state>Ontario</state>
        <zip>L8J 0B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Zizzo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Stoney Creek)</name>
      <address>
        <city>Stoney Creek</city>
        <state>Ontario</state>
        <zip>L8J 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehul Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 0K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lew Pliamm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azhar Toma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Toronto)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azhar Toma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Sabeen Anwar Medicine Professional Corporation</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 1T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabeen Anwar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research&amp; Arthritis Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jude F Rodrigues, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Devonshire Clinical Research Inc.</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Heaton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Quebec)</name>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <zip>G6W 0M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Vallieres, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Mirabel QC)</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Gagne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Recherche GCP Research</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Mazza, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Medical Acadie</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Akhras, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Montreal)</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Breger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Quebec Inc.</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Frechette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Carbonneau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Arsenault, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Victoriaville Inc.</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethel Bellavance, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee</keyword>
  <keyword>WOMAC</keyword>
  <keyword>NSAID</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

